Ethylmethylhydroxypyridine succinate

Other metabolic agents (local RU classification)

ATC code: V03AX-MEXIDOL (Ethylmethylhydroxypyridine succinate (local code))

Mechanism of action

Mexidol is the Russian trade name of 2-ethyl-6-methyl-3-hydroxypyridine succinate, a synthetic molecule developed at the Institute of Biochemical Physics of the Russian Academy of Sciences in the 1980s. The manufacturer claims antioxidant, antihypoxant and membrane-stabilising activity via inhibition of free radical oxidation of lipids and activation of succinate dehydrogenase in the mitochondrial respiratory chain. The molecule is not listed in the USP, European Pharmacopoeia, ATC index or any major international clinical reference. No independent peer-reviewed mechanism-of-action studies in indexed international journals have been published. Mexidol is registered only in Russia and several EAEU countries. All published efficacy trials originate from Russian-language journals, most are single-centre and small, and external methodological reviews have repeatedly flagged high risk of bias.

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Cognitive impairment

Not recommended

Evidence tier F. The diagnostic entity "dyscirculatory encephalopathy" used in Russian neurology to justify long-term mexidol courses is absent from ICD-11 and from the , EAN and frameworks for vascular cognitive impairment. Mexidol is not listed in any international dementia or vascular cognitive impairment guideline. Evidence-based management of vascular cognitive impairment is aggressive control of vascular risk factors, physical activity, treatment of depression and sleep disorders, and structured cognitive engagement.

Sources

AAN: Practice Guideline Update: Mild Cognitive Impairment (2018)

Generalized anxiety disorder

Not recommended

Evidence tier F. Mexidol is not mentioned in any international anxiety guideline ( 2023, CG113, WFSBP). First-line evidence-based therapy for generalized anxiety disorder is cognitive behavioural therapy and SSRIs (sertraline, escitalopram, paroxetine) or SNRIs (venlafaxine, duloxetine), with buspirone and pregabalin as alternatives. Russian "anxiolytic" prescribing of mexidol relies on local trials with high risk of bias and on perceived absence of sedation or dependency, neither of which substitutes for proof of efficacy.

Sources

NICE: Generalised anxiety disorder and panic disorder in adults: management (2019)

Ischemic stroke

Not recommended

Evidence tier F. Mexidol is not mentioned in the 2019 acute ischaemic stroke guideline, the 2021 guideline or any other international stroke guideline. Independent meta-analyses outside Russia have not been published because primary trials are not indexed in MEDLINE or Embase. The class of "neuroprotectants" repeatedly failed to show benefit in stroke RCTs over four decades. Evidence-based acute therapy is reperfusion with alteplase or tenecteplase within 4.5 hours, thrombectomy within 6-24 hours for selected large vessel occlusions, admission to a stroke unit and early secondary prevention.

Sources

Transient ischemic attack

Not recommended

Evidence tier F. Mexidol for TIA is not mentioned in international guidelines (, , ). TIA is a medical emergency: workup focuses on identifying the embolic source (large artery atherosclerosis, atrial fibrillation, cardioembolism), and evidence-based management is urgent antiplatelet or anticoagulant therapy, statin initiation, blood pressure control and lifestyle modification. Adding a non-validated "neuroprotectant" does not change short-term stroke risk and delays evidence-based workup.

Sources

AHA/ASA: Guidelines for the early management of patients with acute ischemic stroke: 2019 update (2019)

Practical notes

Russian practice note

Ethylmethylhydroxypyridine succinate is widely used in Russian neurology and cardiology under the brand names Mexidol, Mexicor, Mexiprim, and Neurox. It is registered in the and included in several Russian Ministry of Health clinical guidelines, creating divergence from international approaches. The molecule is not described as a therapeutic agent in international pharmacological literature.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Official sources

Direct links to regulator labels. Open in a new tab.

AEMPS / CIMA

Spanish Medicines Information Centre (CIMA)

Label dated: 01/03/2026

GRLS

Russian State Register of Medicines

Safety

Contraindications

Severe hepatic disease
Severe renal disease
Pregnancy
Breastfeeding
Pediatric use (per label for most formulations)
Hypersensitivity

Serious adverse effects

Independent data on serious adverse events are limited

Common adverse effects

Nausea
Dry mouth
Somnolence
Allergic reactions

PregnancyFDA N

Contraindicated in pregnancy per manufacturer label. International sources provide no recommendations.

Breastfeeding

There are no data on the transfer of ethylmethylhydroxypyridine succinate into human milk. The drug was developed in Russia in the 1980s, is not registered by the EMA or AEMPS and does not appear in international neurology or cardiology guidelines. Routine use during breastfeeding is not supported; the drug is typically withheld while breastfeeding.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Frequently asked

What is Ethylmethylhydroxypyridine succinate used for?

Ethylmethylhydroxypyridine succinate is evaluated for the following indications with varying evidence strength: Generalized anxiety disorder (evidence tier F), Ischemic stroke (evidence tier F), Transient ischemic attack (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Ethylmethylhydroxypyridine succinate?

Common side effects of Ethylmethylhydroxypyridine succinate (≥ 1 in 100): Nausea, Dry mouth, Somnolence, Allergic reactions. See the Safety section for uncommon and serious reactions.

Is Ethylmethylhydroxypyridine succinate safe during pregnancy?

FDA category N. Contraindicated in pregnancy per manufacturer label. International sources provide no recommendations.

Is Ethylmethylhydroxypyridine succinate compatible with breastfeeding?

Who should not take Ethylmethylhydroxypyridine succinate?

Ethylmethylhydroxypyridine succinate is contraindicated in: Severe hepatic disease; Severe renal disease; Pregnancy; Breastfeeding; Pediatric use (per label for most formulations). Full list in the Safety section.